Last reviewed · How we verify
Sublingual film containing Igalmi
Igalmi is a fast-acting atypical antipsychotic that rapidly dissolves under the tongue to block dopamine and serotonin receptors in the brain.
Igalmi is a fast-acting atypical antipsychotic that rapidly dissolves under the tongue to block dopamine and serotonin receptors in the brain. Used for Acute agitation associated with schizophrenia or bipolar disorder.
At a glance
| Generic name | Sublingual film containing Igalmi |
|---|---|
| Also known as | Dexmedetomidine, BXCL501 |
| Sponsor | BioXcel Therapeutics Inc |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Igalmi (risperidone) is formulated as a sublingual film that bypasses first-pass hepatic metabolism, allowing faster absorption and onset of action compared to oral tablets. It acts as a dopamine D2 and serotonin 5-HT2A receptor antagonist, reducing psychotic symptoms and agitation. The sublingual delivery enables rapid therapeutic effect, making it suitable for acute agitation management.
Approved indications
- Acute agitation associated with schizophrenia or bipolar disorder
Common side effects
- Somnolence
- Akathisia
- Extrapyramidal symptoms
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sublingual film containing Igalmi CI brief — competitive landscape report
- Sublingual film containing Igalmi updates RSS · CI watch RSS
- BioXcel Therapeutics Inc portfolio CI